Loading the player...
Information
Guidelines Update: Medullary Thyroid Cancer – Systemic Therapies
Accreditation
The American Thyroid Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA PRA Category 1 Credits™
The American Thyroid Association designates this live activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Information
In accordance with the ACCME Accreditation Criteria, the American Thyroid Association ensures that anyone in a position to control the content of the educational activity (planners/speakers/authors/discussants/moderators) disclosed all financial relationships with any commercial interest (termed by the ACCME as “ineligible companies”) held in the last 24 months.
The ACCME also requires that ATA manage any reported relevant financial relationships and eliminate the potential for bias during the educational activity. Any relevant financial relationships noted have been mitigated. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation.
Ellen Marqusee – Nothing to disclose
Mimi Hu – Eli Lilly (Research Funding)
Tania Jaber – Nothing to disclose
Ellen Marqusee, MD – Chair
Mimi Hu, MD - Guideline Co-Chair
Mimi Hu, MD graduated from Rice University with a degree in mechanical engineering. She obtained her medical degree from the University of Texas - Houston Health Sciences Center. She completed her residency and endocrine fellowship at Baylor College of Medicine, where she also served as chief medical resident. After completion of her research fellowship at MD Anderson, she joined the faculty in 2007 in the department of Endocrine Neoplasia and Hormonal Disorders. Dr. Hu's clinical expertise is in the evaluation and treatment of patients with thyroid carcinoma (differentiated and medullary), hereditary endocrine neoplasia disorders and metabolic bone and mineral disorders. She is the primary investigator and collaborator on multiple clinical trials evaluating various targeted therapies for advanced thyroid carcinoma. She has published articles and book chapters evaluating the management of medullary thyroid carcinoma, multiple endocrine neoplasia, bone health in cancer patients, endocrine complications of head and neck surgery, and paraneoplastic endocrine disorders. She is the director of the Oncologic Endocrine Fellowship program at MD Anderson, the first-of-its-kind training program to provide specialized education in the care and management of patients with endocrine neoplasias/cancers or endocrine complications from cancer or its treatments.
